Eosinophilic Esophagitis Clinical Trial
Official title:
Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis
Eosinophilic esophagitis is characterized by an eosinophilic infiltration of the esophagus. It presents clinically with a variety of symptoms including dysphagia, emesis, and food impaction. Although the underlying mechanism is different, gastroesophageal reflux can present with similar clinical findings but can be distinguished from eosinophilic esophagitis by the number of eosinophils present on esophageal biopsy. In children, food allergies play a role in exacerbating eosinophilic esophagitis, but the role of food allergies in adults is uncertain. In this study, we aim to determine the prevalence of food allergies in a cohort of adults with eosinophilic esophagitis.
Study Population Male and female subjects, ages 18 years and older with findings of > 15
eosinophils per high powered field by endoscopic esophageal biopsy. Patients should also have
symptoms consistent with eosinophilic esophagitis including dysphagia, heartburn, epigastric
pain, recurrent vomiting, or food impaction. The comparative group will include male and
female subjects, ages 18 years and older with a previous diagnosis of gastroesophageal reflux
with findings of < 15 eosinophils per high power field by endoscopic esophageal biopsy.
Inclusion Criteria
1. Male and female subjects 18 years and older
2. Previous diagnosis of eosinophilic esophagitis with clinical symptoms including
heartburn, dysphagia, vomiting, epigastric pain, recurrent vomiting, food impaction as
well > 15 eosinophils per high powered field (400x magnification) by endoscopic
esophageal biopsy in both the proximal and distal esophagus
3. Previous diagnosis of gastroesophageal reflux with < 15 eosinophils per high powered
field (400x magnification) by endoscopic biopsy
Exclusion Criteria
1. Male and female subjects less than 18 years of age
2. Pregnant female subjects
3. Subjects who are receiving systemic steroids and are unable to stop prior to enrollment
4. Subjects who are receiving systemic antihistamines and are unable to stop prior to
enrollment
5. Subjects who are unable to cooperate/comply with study procedures or communicate with
investigator in order to successfully complete the study
6. Subjects with severe skin disorders such as atopic dermatitis, dermatographism, or
psoriasis who would be unable to complete skin or patch testing
7. Subjects with an infirmity, disability, or geographical location which seems likely to
prevent regular attendance for patient visit Risks Skin testing with prick methodology
has a risk of systemic reaction of less than 0.1% per 40 tests, however, no deaths have
been reported with this method of testing. Systemic reactions are readily treated using
Injectable epinephrine with oral antihistamines and oral corticosteroids (prednisone).
Patch testing has no known associated risk for development of systemic reactions.
Phlebotomy is associated with a minimal risk of bleeding, significant local discomfort,
and infection from the needle puncture.
Benefits Treatment options for adults with eosinophilic esophagitis are limited. Food
allergies are a known contributor to this disorder in children and a better understanding of
food allergies in adult subjects may provide additional treatment options.
Adverse Events and Withdrawal Criteria All subjects will be assessed for adverse events at
each study visit. If any adverse events are experienced by the subject, the investigator will
document the event within the subject's file and promptly report the event to the IRB. The
investigators involved with this study will determine if a participant needs to be withdrawn
from the study based upon the subject's health and medical history.
Sample Size Sample size estimation is based on the assumption that up to 50% of adults with
eosinophilic esophagitis (EE) will have a positive skin test to food and 10% of adults
without EE will have a positive skin test to food. With this assumption, a total of 40
subjects are needed, 20 per group, in order to achieve at least 80% power with two sided test
at alpha level of 0.05 and beta 0.2.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03382678 -
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
|
||
Completed |
NCT05083312 -
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
|
Phase 3 | |
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT03633617 -
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
Terminated |
NCT04543409 -
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
|
Phase 3 | |
Completed |
NCT04941742 -
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)
|
||
Terminated |
NCT02314455 -
Esophageal Absorption in EoE
|
N/A | |
Completed |
NCT01953575 -
Mucosal Impedance and Eosinophilic Esophagitis
|
N/A | |
Completed |
NCT01386112 -
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04991935 -
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
|
Phase 3 | |
Not yet recruiting |
NCT05896891 -
San Raffaele EoE Biobank
|
||
Active, not recruiting |
NCT05482256 -
A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis
|
N/A | |
Recruiting |
NCT05485155 -
Zemaira Eosinophilic Esophagitis Pilot Study
|
Phase 2 | |
Recruiting |
NCT04149470 -
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
|
Phase 4 | |
Recruiting |
NCT04416217 -
Eosinophilic Esophagitis Steroid Safety Study
|
||
Completed |
NCT05084963 -
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Recruiting |
NCT02331849 -
Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.
|
N/A | |
Active, not recruiting |
NCT02202590 -
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
|
N/A | |
Active, not recruiting |
NCT05176249 -
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
|